S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
Log in

Concert Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CNCE)

$6.66
+0.29 (+4.55 %)
(As of 10/17/2019 04:00 PM ET)
Today's Range
$6.32
Now: $6.66
$6.71
50-Day Range
$5.53
MA: $8.74
$12.16
52-Week Range
$5.36
Now: $6.66
$17.83
Volume187,206 shs
Average Volume230,656 shs
Market Capitalization$158.51 million
P/E RatioN/A
Dividend YieldN/A
Beta0.9
Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CNCE
CUSIPN/A
Phone781-860-0045

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.51 million
Book Value$7.16 per share

Profitability

Net Income$-56,020,000.00
Net Margins-7,303.34%

Miscellaneous

Employees71
Market Cap$158.51 million
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable

Receive CNCE News and Ratings via Email

Sign-up to receive the latest news and ratings for CNCE and its competitors with MarketBeat's FREE daily newsletter.


Concert Pharmaceuticals (NASDAQ:CNCE) Frequently Asked Questions

What is Concert Pharmaceuticals' stock symbol?

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

How were Concert Pharmaceuticals' earnings last quarter?

Concert Pharmaceuticals Inc (NASDAQ:CNCE) released its earnings results on Thursday, August, 1st. The biotechnology company reported ($0.78) earnings per share for the quarter, beating analysts' consensus estimates of ($0.92) by $0.14. The biotechnology company earned $0.05 million during the quarter, compared to analyst estimates of $0.30 million. Concert Pharmaceuticals had a negative return on equity of 49.44% and a negative net margin of 7,303.34%. View Concert Pharmaceuticals' Earnings History.

When is Concert Pharmaceuticals' next earnings date?

Concert Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Concert Pharmaceuticals.

What price target have analysts set for CNCE?

7 Wall Street analysts have issued 1 year price objectives for Concert Pharmaceuticals' stock. Their predictions range from $8.00 to $25.00. On average, they expect Concert Pharmaceuticals' stock price to reach $16.29 in the next twelve months. This suggests a possible upside of 144.5% from the stock's current price. View Analyst Price Targets for Concert Pharmaceuticals.

What is the consensus analysts' recommendation for Concert Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Concert Pharmaceuticals.

What are Wall Street analysts saying about Concert Pharmaceuticals stock?

Here are some recent quotes from research analysts about Concert Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States. " (10/1/2019)
  • 2. HC Wainwright analysts commented, "Our price target of $29/share is comprised of $10.39 from CTP-543 in AA + $3.81 from AVP-786 in AD + $8.60 in schizophrenia + $5.75 in cash and is based on a discounted cash flow analysis (2019-2026) using a 12% discount rate and 1% growth rate, in line with the expected discount and growth parameters of a development stage biotechnology company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) smaller than anticipated commercial opportunity due to market size, competition, and pricing." (8/2/2019)
  • 3. Mizuho analysts commented, "We do not see earnings as the most meaningful indicator of value for developmental stage biotechs. Catalysts to watch: 1) CTP-543 Phase II data for alopecia areata (AA) is expected in 3Q19, 2) AVP-786 second Phase III trial is expected to complete in Dec 2019, data could be available in early 2020. Concert had $153.8mn at the end of 1Q19 which is expected to support operation through 2H20." (5/3/2019)

Has Concert Pharmaceuticals been receiving favorable news coverage?

Media stories about CNCE stock have trended very negative on Thursday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Concert Pharmaceuticals earned a news impact score of -3.1 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Concert Pharmaceuticals.

Are investors shorting Concert Pharmaceuticals?

Concert Pharmaceuticals saw a drop in short interest during the month of September. As of September 30th, there was short interest totalling 927,900 shares, a drop of 9.0% from the August 30th total of 1,020,000 shares. Based on an average daily volume of 208,700 shares, the short-interest ratio is currently 4.4 days. Approximately 4.4% of the shares of the stock are short sold. View Concert Pharmaceuticals' Current Options Chain.

Who are some of Concert Pharmaceuticals' key competitors?

What other stocks do shareholders of Concert Pharmaceuticals own?

Who are Concert Pharmaceuticals' key executives?

Concert Pharmaceuticals' management team includes the folowing people:
  • Mr. Richard H. Aldrich Mba, Co-Founder & Chairman (Age 65)
  • Dr. Roger D. Tung, Co-Founder, CEO, Pres & Director (Age 59)
  • Ms. Nancy Stuart, Chief Operating Officer (Age 61)
  • Dr. James V. Cassella, Chief Devel. Officer (Age 64)
  • Mr. Marc A. Becker, Chief Financial Officer (Age 47)

Who are Concert Pharmaceuticals' major shareholders?

Concert Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Ingalls & Snyder LLC (6.44%). Company insiders that own Concert Pharmaceuticals stock include Bvf Partners L P/Il, Heek Christi Van, James V Cassella, Nancy Stuart, Peter Barton Hutt, Richard Aldrich, Ronald W Barrett and Value Fund L P Biotechnology. View Institutional Ownership Trends for Concert Pharmaceuticals.

Which institutional investors are buying Concert Pharmaceuticals stock?

CNCE stock was acquired by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC. Company insiders that have bought Concert Pharmaceuticals stock in the last two years include Heek Christi Van, Richard Aldrich and Value Fund L P Biotechnology. View Insider Buying and Selling for Concert Pharmaceuticals.

How do I buy shares of Concert Pharmaceuticals?

Shares of CNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Concert Pharmaceuticals' stock price today?

One share of CNCE stock can currently be purchased for approximately $6.66.

How big of a company is Concert Pharmaceuticals?

Concert Pharmaceuticals has a market capitalization of $158.51 million and generates $10.51 million in revenue each year. The biotechnology company earns $-56,020,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis. Concert Pharmaceuticals employs 71 workers across the globe.View Additional Information About Concert Pharmaceuticals.

What is Concert Pharmaceuticals' official website?

The official website for Concert Pharmaceuticals is http://www.concertpharma.com/.

How can I contact Concert Pharmaceuticals?

Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-860-0045 or via email at [email protected]


MarketBeat Community Rating for Concert Pharmaceuticals (NASDAQ CNCE)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  395 (Vote Outperform)
Underperform Votes:  317 (Vote Underperform)
Total Votes:  712
MarketBeat's community ratings are surveys of what our community members think about Concert Pharmaceuticals and other stocks. Vote "Outperform" if you believe CNCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel